Efficacy and effects of Ramucirumab

1. Stomach or gastroesophageal junction (GEJ) adenocarcinoma:

Ramucirumab is indicated as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction who have disease progression during or after prior fluoropyrimidine- or platinum-containing chemotherapy. The average survival time of patients treated with ramucirumab and paclitaxel in the study was 9.6 months.

2. Non-small cell lung cancer (NSCLC):

(1) Ramosumab is indicated in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors harbor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Patients in the study who received ramucirumab and erlotinib lived an average of 19 months without their cancer getting worse.

(2) is also indicated in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities should have disease progression on an FDA-approved treatment for these abnormalities before receiving ramucirumab.

3. Colorectal cancer (mCRC):

Ramuscumab in combination withFOLFIRI (irinotecan, leucovorin, and fluorouracil) is indicated for the treatment of patients with metastatic colorectal cancer whose disease has progressed before or after treatment with bevacizumab, oxaliplatin, and fluoropyrimidine. In the study, patients treated with ramucirumab and FOLFIRI had an average survival time of 13.3 months.

4. Hepatocellular carcinoma (HCC):

As a single agent, ramucirumab is indicated for the treatment of patients with hepatocellular carcinoma who have alpha-fetoprotein (AFP) ≥ 400ng/mL and have been treated with sorafenib. The average survival time of patients who received ramucirumab in the study was 8.5 months.